Results: KMK

Search articles by EPIC code

Kromek – is “foreseeable future” this time longer than three and a half months?...

Previously writing on group now describing itself as “a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments” Kromek (KMK), in July with the shares down towards 15p I reviewed “well-placed to capitalise on the substantial opportunities”, concluding still a sell. It today provides an update, with its year ended 30th April.


Kromek – argues cash “slightly ahead of market expectations”… but what does that mean?!

Detection technology group Kromek (KMK) has announced “significant sequential revenue growth in H2 over H1 2020/21 and expects to report revenue and EBITDA for the year ended 30 April 2021 in line with market expectations. The group continues to maintain tight cost control, improve collections and manage cash flow, and this conscientious management has resulted in the group's cash position at 30 April 2021 being slightly ahead of market expectations”. Sounds good... but, with how creditable this performance is naturally dependent on the expectations, what are they?...

Page 1 of 2 (19 articles)
Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Complete Coverage

Recent Comments